title: Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis.
abstract: The sustained antibody response to nuclear envelope gp210 antigen indicates a group of primary biliary cirrhosis (PBC) patients at high risk for the progression to end-stage hepatic failure. To address this issue, we immunohistochemically studied the expression of gp210 antigen in needle liver biopsy specimens from PBC patients using a monoclonal antibody specific for gp210 antigen. The specimens from autoimmune hepatitis (AIH), chronic viral hepatitis B (CHB) and C (CHC) patients served as disease controls. The expression of gp210 antigen was apparently increased on the nuclear envelope of biliary epithelial cells (BECs) of small bile ducts in almost all specimens from PBC. In contrast, the expression of gp210 antigen was negative in BECs of small bile ducts in normal liver, while relatively weak anti-gp210 immunostaining was observed in AIH, CHC and CHB. In addition, the degree of gp210 expression in BECs of small bile ducts was positively correlated to that of portal inflammation, interface hepatitis and lobular inflammation in PBC. These results indicate that the increased expression of gp210 in small bile ducts, which is probably associated with damage to BECs by inflammation, is possibly involved in autoimmune response to gp210 leading to the progression to end-stage hepatic failure in PBC.
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan. nakamuram@nmc.hosp.go.jp
authors.forename: Minoru
authors.initials: M
authors.lastname: Nakamura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Takii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ito
authors.forename: Atsumasa
authors.initials: A
authors.lastname: Komori
authors.forename: Terufumi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Yuki
authors.initials: Y
authors.lastname: Shimizu-Yoshida
authors.forename: Makiko
authors.initials: M
authors.lastname: Koyabu
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Matsuyama
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Mori
authors.forename: Takashi
authors.initials: T
authors.lastname: Kamihira
authors.forename: Manabu
authors.initials: M
authors.lastname: Daikoku
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Migita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yatsuhashi
authors.forename: Naohito
authors.initials: N
authors.lastname: Nozaki
authors.forename: Shinji
authors.initials: S
authors.lastname: Shimoda
authors.forename: Hiromi
authors.initials: H
authors.lastname: Ishibashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000276:immunology; D001648:Bile Canaliculi / Q000276:immunology*; D001707:Biopsy, Needle; D005260:Female; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000473:pathology; D019693:Hepatitis, Autoimmune / Q000276:immunology / Q000473:pathology; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000276:immunology* / Q000473:pathology; D017093:Liver Failure / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000737:chemistry / Q000276:immunology; D008875:Middle Aged; D008969:Molecular Sequence Data; D028861:Nuclear Pore Complex Proteins; D009687:Nuclear Proteins / Q000032:analysis* / Q000737:chemistry / Q000276:immunology; D011379:Prognosis
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D008562:Membrane Glycoproteins; C063865:NUP210 protein, human; D028861:Nuclear Pore Complex Proteins; D009687:Nuclear Proteins